In the current project we will use UGent technology (UGent IP) to provide an industrial proof-of-concept for its use in the development of an ELISA assay with substantially increased sensitivity. During the project there will be close collaboration with a Flemish Biotech company that is active in the IVD market. Company X will be granted a license option in their domain, while through this interdisciplinary approach Ugent will be given the opportunity to demonstrate the usefulness of furan technology in immunoassys, which can be further used in domains outside of the company . The oriented immobilization of antibodies and recombinant proteins through the use of the furan crosslink technology illustrated here will be of interest to multiple technologies in various fields of application which will give rise to different licensing options.